Enterohepatic circulation model for population pharmacokinetic analysis.
An enterohepatic circulation model based on physiological aspects of biliary excretion has been developed for population pharmacokinetic analysis. Mycophenolate mofetil was selected as a model drug for validation of the model. As a secondary objective, the model was used for pharmacokinetic comparison among different races. The post-hoc plasma concentration-time course was well described by the newly developed enterohepatic model and a secondary peak arising from enterohepatic circulation was also well defined. The covariates predicted by the model agreed well with literature results. The model is useful for evaluation of the covariates of an enterohepatically circulated drug. The population pharmacokinetic approach is of benefit for evaluating racial differences for a pharmacokinetic bridging package.
Funaki
T
T
Clinical Pharmacology Group, Nippon Roche K. K., Tokyo, Japan.
D000328:Adult; D004764:Enterohepatic Circulation / Q000502:physiology*; D005006:Ethnicity; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011355:Prodrugs / Q000493:pharmacokinetics*; D044469:Racial Groups; D015203:Reproducibility of Results
D007166:Immunosuppressive Agents; D011355:Prodrugs; D009173:Mycophenolic Acid